Surgical orchiectomy vs. medical castration in treatment of metastatic prostate cancer

A new study in JAMA Oncology has suggested that surgical orchiectomy may have lower risk for complications and side effects than medical castration with LHRH agonists (also known as GnRH agonists) like leuprolide acetate (Lupron) and others in treatment of men newly diagnosed with metastatic prostate cancer. This is a complex issue! … READ MORE …

Is possible new prostate cancer vaccine really “promising”?

A new article on the Medscape Oncology web site (and again correlated with a media release sent out by the European Association for Urology [EAU] from their annual meeting in Milan, Italy) is headed “Prostate cancer vaccine shows promise.” However, the degree of that “promise” appears to be open to some question. … READ MORE …

Should we be calling “hormone therapy” for prostate cancer a spade?

When women and their doctors talk about “hormone therapy” they are most commonly referring to the (now) highly controversial issue of whether hormonal supplements (estrogen and progesterone) should be used at and after menopause to prevent the symptoms of menopause and/or later risks related to heart disease and osteoporesis. … READ MORE …

Rats to you … a critical ADT research finding

Sometimes there is a piece of research published that provides truly astonishing data for members of the prostate cancer community. The following report is NOT one of these — unless you are a laboratory rat or can appreciate the potential implications for professional, long-distance cyclists. … READ MORE …

Language, masculinity, and prostate cancer therapy: a social perspective

A recent article in the International Journal of Men’s Health argues that we need to be more honest with patients about the impact of “hormone therapy” in the treatment of prostate cancer. … READ MORE …

GTx says selective estrogen receptor agonist induces medical castration

According to a Reuters report based on a recent media release from GTx, the investigational agent GTx-758 is able to induce temporary medical castration in healthy volunteers, making this agent yet another possible candidate for the hormonal management of progressive prostate cancer. … READ MORE …

Thursday’s prostate cancer news: November 13, 2008

Today’s reports include items on:

  • Perceptions of pain and discomfort in men undergoing DRE
  • 10-year survival data of men with pT3 disease treated initially with a radical prostatectomy
  • Orchiectomy, medical castration, and acceptable social costs
  • Hemi-body radiation to treat pain in men with multiple bone metastases … READ MORE …